LifeStance Q4 revenue $280.6M (+22% YoY); net loss $45M; guides FY24 revenue $1.19-$1.24B

LifeStance Health Group, Inc.

Q4 revenue $280.6M (+22% YoY); full-year revenue $1,055.7M (+23%).
Q4 net loss $45.0M; full-year net loss $186.3M. Adjusted EBITDA $20.3M (Q4) and $59.0M (FY).
Added 227 net clinicians in Q4, 1,014 in FY; total clinicians 6,645 (+18% YoY).
FY2024 guidance: revenue $1.19-$1.24B, Center Margin $345-$365M, Adj. EBITDA $80-$90M, positive free cash flow.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LifeStance Health Group, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $280.6 million, net income Net loss of $45.0 million. Guidance initiated.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: $280.6 million
Net income: Net loss of $45.0 million
Guidance: initiated
Result: reported results

Exact text from the filing

full year ended December 31, 2023. (All results compared to prior-year comparative period, unless otherwise noted) 2023 Highlights and 2024 Outlook • Fourth quarter revenue of $280.6 million increased 22% and full year revenue of $1,055.7 million increased 23% compared to revenue of $859.5 million • Clinician base increased 18% to 6,645 clinicians, including 227 net

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

LifeStance Health Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-021511

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.